Pharmaceutical Open Innovation Test Bed for Enabling Nano-pharmaceutical Innovative Products

PHOENIX aims to enable the seamless, timely and cost-friendly transfer of nano-pharmaceuticals from lab bench to clinical trials by providing necessary advanced, affordable and easily accessible services through the Phoenix-OITB (open-innovation test-bed), that will be established as a novel legal entity in 2022.
Phoenix-OITB will offer a Single Entry Point for a consolidated network of facilities, technologies, services and expertise for all the technology transfer aspects from characterization, testing, verification up to scale-up, GMP compliant manufacturing and regulatory guidance.
The developments will we achieved in concrete work on 5 demo-cases with industry and SMEs; two open calls will be issued in the second half of the project.
RECENDT will contribute to the PHOENIX-targets by the development and application of analytical methods in the field of IR- & Raman-spectroscopic technologies, which shall later also be offered in the Phoenix-OITB service portfolio. Further, RECENDT will support in communication, dissemination and reach-out to the existing network in Austria.

Facts and Figures

  • Duration: 4 Jahre (01.03.2021 - 28.02.2025)
  • Funding: EU (H2020)
  • Projectpartner: 6 Company Partners; 6 Scientific Partners
  • Projectwebsite:


Company Partners:

⇒ Cenya Imaging
⇒ MyBiotech GmbH
⇒ Topas Therapeuthics GmbH
⇒ NANOMOL Technologies
⇒ LeanBioPro Company
⇒ Grace Bio S.L.

Scientific Partners:

⇒ BioNanoNet Forschungsgesellschaft mbH
⇒ CSIC Instituto de Nanociencia y Materiales de Aragon
⇒ Institute for Medical Research and Occupational Health
⇒ Luxembourg Institute of Science and Technology
⇒ RECENDT - Research Center for Non-Destructive Testing GmbH
⇒ Research Center for Pharmaceutical Engineering (RCPE)